MTOR and prostate carcinoma: For example, combining HDAC inhibitors and LY294002 (a PI3K inhibitor) sensitizes a non-small cell lung cancer (NSCLC) xenograft to apoptosis [26]; in prostate cancer, HDAC inhibitor produces greater antitumor activity when combines with PI3K/mTOR inhibitor [27].